NICE, NHS England and NHS Improvement and PTC Therapeutics (the Company) have reached an agreement that will extend the Managed Access Agreement (MAA) for Translarna (ataluren) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. This agreement extends the MAA, that was originally scheduled to end in July 2021, to January 2023. This will enable PTC Therapeutics to access more complete data in preparation for their resubmission to NICE and the re-evaluation of ataluren before the end of the MAA, the outcome of which will determine how ataluren will be commissioned in the long term.